Cirrhotic patients who are hospitalized for Acute on chronic liver failure (ACLF) research hub

Randomized, placebo-controlled, double blind, multi-centre Phase IIb stuDy to evaluate the efficacy and safety of HepaStem in patients with Acute on Chronic Liver Failure (ACLF) – DHELIVER

This study, called DHELIVER, is testing a new treatment, HepaStem, for people with severe liver failure called ACLF. It aims to see if HepaStem can help people live longer and improve their liver health.